The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation

Journal of Oncology Pharmacy Practice

Volumn 20, Issue 4, 2014, Pages 257-262

  Wilhelm, Kaci ^a   Chemaly, Roy ^a   Saliba, Rima ^a   Gulbis, Alison ^a   Saunders, Ila ^a   Cool, Rita ^a   Ferguson, Jill ^a   Westmoreland, Michael ^a   Rondon, Gabriela ^a   Kebriaei, Partow ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic stem cell transplant; Cytomegalovirus; Valganciclovir

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; VALGANCICLOVIR;

ADULT; AGED; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CYTOMEGALOVIRUS INFECTION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84905666739     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155213501360     Document Type: Article

References (11)

1. Hiemenz J. Management of infections complicating allogeneic hematopoietic stem cell transplantation. Semin Hematol 2009; 46: 289-312
2. Boeckh M, Nichols W, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003; 9: 543-558
3. George B, Pati N, Gilroy N, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010; 12: 322-329
4. Jacobsen T and Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health-Syst Pharm 2010; 67: 1417-1425
5. Manuel O, Venetz J-P, Fellay J, et al. Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus/mycophenoalte-based regimen in kidney transplantation. Swiss Med Wkly 2007; 127: 669-676
6. Verma A, Devine S, Morrow M, et al. Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplant. Role of pretransplant ganciclovir and post-transplant acyclovir. Bone Marrow Transplant 2003; 31: 813-816
7. Winston D, Ho W, Bartoni K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Int Med 1993; 118: 179-184
8. Zaia J, Baden L, Boeckh MJ, et al. Viral disease prevention after HCT. Bone Marrow Transplant 2009; 44: 471-482
9. Giralt S, Ballen K, Rizzo D, et al. Reduced intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367-369
10. Ljungman P, Griffiths P and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097
11. Pollack M, Heugel J, Xie H, et al. An international comparison of current strategies to prevent herspesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 664-673